Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Moderna (NASDAQ:MRNA) is planning to launch a messenger-RNA-based vaccine for skin cancer as early as next year, Japanese ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Under the original personal cancer vaccine (PCV) agreement in 2016, Merck made a cash payment to Moderna of $200 million to discover and develop individually tailored cancer vaccines for patients ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

Merck's vaccine, branded as Ervebo, is recommended by the World Health Organization's (WHO's) Strategic Advisory Group of Experts on Immunization for those at risk of Ebola exposure during outbreaks.

Merck’s (NYSE:MRK) human papillomavirus (HPV) vaccine Gardasil 9 has met key efficacy goals in a pivotal late-stage trial involving Japanese males ages 16 to 26 years. The Phase 3 V503-064 trial ...

Other studies show that rVSV-ZEBOV vaccine reduces the risk of death in Ebola patients who were vaccinated before and even after exposure. Merck & Co Inc’s MRK rVSV-ZEBOV vaccine is the only WHO ...

Human papillomavirus (virus like particle, 9-valent) vaccine is under clinical development by Merck and currently in Phase II for Human Papillomavirus Infections.

According to GlobalData, the recombinant vesicular stomatitis virus – Zaire Ebola virus (rVSV-ZEBOV) vaccine is marketed by Merck under the name Ervebo. It has been available in the US and EU ...

The Cambridge, Massachusetts-based biotech has already reported encouraging mid-stage data for its personalized cancer vaccine, named mRNA-4157, in combination with Merck's (NYSE:MRK) anti-PD1 ...